Statistical properties of continuous composite scales and implications for drug development
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Little research has been conducted on the statistical properties of composite measures comprising linear combinations of continuous component scales. We assessed the quantitative relationship between the composites and their individual components regarding their abilities to detect treatment effects. In particular, we developed the mathematical derivation of the treatment effect size of a continuous composite in relation to the treatment effect sizes of its components and proved multiple properties of the composite. We demonstrated that the treatment effect size of a composite is greater than the minimum treatment effect size of its components and that above certain thresholds of correlations of components and ratios of component effect sizes, the composite may outperform its components. Examples from Alzheimer's disease (AD) clinical studies of solanezumab and donepezil using the composite Integrated AD Rating Scale (iADRS) and its components, the AD Assessment Scale-Cognitive subscale (ADAS-Cog) and AD Cooperative Study-Activities of Daily Living inventory, instrumental items (ADCS-iADL) were consistent with the theoretical statistical properties. The understanding of the quantitative relationships between continuous composites and their components will be useful in clinical trial design and the development of new scales and composites across therapeutic areas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668 · cited 1×
“…studies The solanezumab EXPEDITION (NCT00905372) and EXPEDITION2 (NCT00904683) studies were Phase 3, placebo-controlled studies investigating solanezumab treatment in patients withmild-to-moderate AD (Mini Mental State Examination [MMSE] 16 through 26) over 80 weeks (Doody et al., 2014).”
BackgroundSelf-citationThe Preclinical Alzheimer Cognitive Composite: Measuring Amyloid-Related Decline
Donohue, M. C., Sperling, R. A., Salmon, D. P., Rentz, D. M., Raman, R., Thomas, R. G., Weiner, M., & Aisen, P. S. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.803 · Cited by 860
Self-citationPrevalence of Amyloid PET Positivity in Dementia Syndromes: A Meta-analysis
Ossenkoppele, R., Jansen, W. J., Rabinovici, G. D., Knol, D. L., van der Flier, W. M., van Berckel, B. N. M., Scheltens, P., Visser, P. J., Verfaillie, S. C. J., Zwan, M. D., et al. (2015) · JAMA · doi:10.1001/jama.2015.4669 · Cited by 677
Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients
Siemers, E. R., Sundell, K. L., Carlson, C., Case, M., Sethuraman, G., Liu‐Seifert, H., Dowsett, S. A., Pontecorvo, M. J., Dean, R. A., & Demattos, R. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.06.1893 · Cited by 370 · cited 3×
“The correlations were estimated from a joint longitudinal model of ADAS-Cog14 and ADCS-iADL, using a similar framework to the MMRM analysis described above, with the exception that the joint model did not include terms for baseline and study.”
Self-citation
Cited by
Donanemab in Early Alzheimer’s Disease
Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100708 · Cited by 1,728
Self-citationShcherbinin, S., Evans, C. D., Lu, M., Andersen, S. W., Pontecorvo, M. J., Willis, B. A., Gueorguieva, I., Hauck, P. M., Brooks, D. A., Mintun, M. A., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.2793 · Cited by 210
Self-citationHerrera, C., DuBois, D. L., Heubach, J., & Grossman, J. B. (2023) · Children and Youth Services Review · doi:10.1016/j.childyouth.2022.106742 · Cited by 35
McLaughlin, J., Scotton, W. J., Ryan, N. S., Hardy, J. A., & Shoai, M. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.14314 · Cited by 11
Metadata
- Authors
- Liu-Seifert, H., Andersen, S., Case, M., Sparks, J., Holdridge, K. C., Wessels, A. M., Hendrix, S., Aisen, P., & Siemers, E.
- Venue
- Journal of Biopharmaceutical Statistics
- Publisher
- Informa UK Limited
- Published
- 2017-04-27
- Volume
- 27
- Issue
- 6
- Pages
- 1104-1114
- ISSN
- 1054-3406 (ISSN-L)
- 1520-5711
- OpenAlex
- W2606298459
- Cited by
- 24
- References
- 4
- FWCI
- 0.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Statistical properties of continuous composite scales and implications for drug development. https://app.cochat.ai/papers/10.1080/10543406.2017.1315819
- The paper
- Liu-Seifert, H., Andersen, S., Case, M., Sparks, J., Holdridge, K. C., Wessels, A. M., Hendrix, S., Aisen, P., & Siemers, E. (2017). Statistical properties of continuous composite scales and implications for drug development. Journal of Biopharmaceutical Statistics. https://doi.org/10.1080/10543406.2017.1315819
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.